Neoantigen Based Therapies Summit

Key Topics

• Targeting ERAP1 to Alter the Cancer Immunopeptidome
• Taking a Comparative Oncological Perspective to Understand the Significance of Neoantigens in Cancer Immunotherapy
• Maximizing Immunogenicity to Drive Clinical Development & Success
• Evaluating Current Neoantigen Identification & Prediction Approaches to Reveal Lessons Learned from Pre-clinical Studies
• The Challenges of Checkpoint Inhibitors: The ATLAS™ Bioassay Method for Identification of Neoantigens & Inhibigens
• Comparison of the Different Delivery Platforms
• Scaling up Safe & Efficacious TCR Therapies Using the Sleeping Beauty Platform
• Overcoming Immunosuppression in the Solid Tumor Microenvironment
• Identifying Functional Neo-antigens by HTS: the Unique, the Common, the Exotic
• Mechanisms of Immune Resistance in NSCLC Through Analysis of the T Cell Repertoire